Cargando…
PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas
The HER receptors are of therapeutic and prognostic significance in breast cancer, and their function is modulated by cytoplasmic tyrosine kinases like PTK6 (brk). We performed a retrospective study on archival breast cancer samples from patients with long follow-up and compared the protein expressi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360069/ https://www.ncbi.nlm.nih.gov/pubmed/17299391 http://dx.doi.org/10.1038/sj.bjc.6603613 |
_version_ | 1782152956482682880 |
---|---|
author | Aubele, M Auer, G Walch, A K Munro, A Atkinson, M J Braselmann, H Fornander, T Bartlett, J M S |
author_facet | Aubele, M Auer, G Walch, A K Munro, A Atkinson, M J Braselmann, H Fornander, T Bartlett, J M S |
author_sort | Aubele, M |
collection | PubMed |
description | The HER receptors are of therapeutic and prognostic significance in breast cancer, and their function is modulated by cytoplasmic tyrosine kinases like PTK6 (brk). We performed a retrospective study on archival breast cancer samples from patients with long follow-up and compared the protein expression between individual HERs and between HERs and the PTK6. Univariate and multivariate analyses were used to study the prognostic value of parameters. Metastases-free survival of patients for longer than 240 months was inversely associated (P⩽0.05) with nodal status, tumour size, and oestrogen receptor status, but was also directly associated with high protein expression levels of HER4 and PTK6 in Kaplan–Meier analysis. In multivariate analysis for metastases-free survival of >240 months, the stepwise selected parameters were tumour size (relative risk 3.1), PTK6 expression (0.4), and number of positive lymph nodes (1.2). Furthermore, we demonstrated a timedependence of the prognostic value attributed to the parameters. The HER receptors (HER2,4), but not PTK6, were independent prognostic markers for metastases-free survival at 60 months, whereas at 240 months PTK6 is the strongest prognostic marker. We demonstrate that PTK6 is a prognostic marker of metastases-free survival in breast cancer, and is independent of the classical morphological and molecular markers of lymph node involvement, tumour size, and HER2 status. |
format | Text |
id | pubmed-2360069 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23600692009-09-10 PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas Aubele, M Auer, G Walch, A K Munro, A Atkinson, M J Braselmann, H Fornander, T Bartlett, J M S Br J Cancer Molecular Diagnostics The HER receptors are of therapeutic and prognostic significance in breast cancer, and their function is modulated by cytoplasmic tyrosine kinases like PTK6 (brk). We performed a retrospective study on archival breast cancer samples from patients with long follow-up and compared the protein expression between individual HERs and between HERs and the PTK6. Univariate and multivariate analyses were used to study the prognostic value of parameters. Metastases-free survival of patients for longer than 240 months was inversely associated (P⩽0.05) with nodal status, tumour size, and oestrogen receptor status, but was also directly associated with high protein expression levels of HER4 and PTK6 in Kaplan–Meier analysis. In multivariate analysis for metastases-free survival of >240 months, the stepwise selected parameters were tumour size (relative risk 3.1), PTK6 expression (0.4), and number of positive lymph nodes (1.2). Furthermore, we demonstrated a timedependence of the prognostic value attributed to the parameters. The HER receptors (HER2,4), but not PTK6, were independent prognostic markers for metastases-free survival at 60 months, whereas at 240 months PTK6 is the strongest prognostic marker. We demonstrate that PTK6 is a prognostic marker of metastases-free survival in breast cancer, and is independent of the classical morphological and molecular markers of lymph node involvement, tumour size, and HER2 status. Nature Publishing Group 2007-03-12 2007-02-13 /pmc/articles/PMC2360069/ /pubmed/17299391 http://dx.doi.org/10.1038/sj.bjc.6603613 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Aubele, M Auer, G Walch, A K Munro, A Atkinson, M J Braselmann, H Fornander, T Bartlett, J M S PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas |
title | PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas |
title_full | PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas |
title_fullStr | PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas |
title_full_unstemmed | PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas |
title_short | PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas |
title_sort | ptk (protein tyrosine kinase)-6 and her2 and 4, but not her1 and 3 predict long-term survival in breast carcinomas |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360069/ https://www.ncbi.nlm.nih.gov/pubmed/17299391 http://dx.doi.org/10.1038/sj.bjc.6603613 |
work_keys_str_mv | AT aubelem ptkproteintyrosinekinase6andher2and4butnother1and3predictlongtermsurvivalinbreastcarcinomas AT auerg ptkproteintyrosinekinase6andher2and4butnother1and3predictlongtermsurvivalinbreastcarcinomas AT walchak ptkproteintyrosinekinase6andher2and4butnother1and3predictlongtermsurvivalinbreastcarcinomas AT munroa ptkproteintyrosinekinase6andher2and4butnother1and3predictlongtermsurvivalinbreastcarcinomas AT atkinsonmj ptkproteintyrosinekinase6andher2and4butnother1and3predictlongtermsurvivalinbreastcarcinomas AT braselmannh ptkproteintyrosinekinase6andher2and4butnother1and3predictlongtermsurvivalinbreastcarcinomas AT fornandert ptkproteintyrosinekinase6andher2and4butnother1and3predictlongtermsurvivalinbreastcarcinomas AT bartlettjms ptkproteintyrosinekinase6andher2and4butnother1and3predictlongtermsurvivalinbreastcarcinomas |